Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. More Details
Outstanding track record with moderate growth potential.
Share Price & News
How has Oncodesign Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALONC is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ALONC's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ALONC underperformed the French Biotechs industry which returned 35.7% over the past year.
Return vs Market: ALONC underperformed the French Market which returned 48.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Oncodesign Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StDeclining Stock and Solid Fundamentals: Is The Market Wrong About Oncodesign Société Anonyme (EPA:ALONC)?
2 months ago | Simply Wall StAre Oncodesign Société Anonyme (EPA:ALONC) Investors Paying Above The Intrinsic Value?
6 months ago | Simply Wall StDeclining Stock and Decent Financials: Is The Market Wrong About Oncodesign Société Anonyme (EPA:ALONC)?
Is Oncodesign Société Anonyme undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALONC (€11.64) is trading below our estimate of fair value (€14.35)
Significantly Below Fair Value: ALONC is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ALONC is poor value based on its PE Ratio (48.5x) compared to the European Biotechs industry average (31.5x).
PE vs Market: ALONC is poor value based on its PE Ratio (48.5x) compared to the French market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: ALONC is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: ALONC is overvalued based on its PB Ratio (9x) compared to the FR Biotechs industry average (4.3x).
How is Oncodesign Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALONC's forecast earnings growth (15% per year) is above the savings rate (0.4%).
Earnings vs Market: ALONC's earnings (15% per year) are forecast to grow slower than the French market (19.3% per year).
High Growth Earnings: ALONC's earnings are forecast to grow, but not significantly.
Revenue vs Market: ALONC's revenue (11.4% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: ALONC's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALONC's Return on Equity is forecast to be very high in 3 years time (717.8%).
How has Oncodesign Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALONC has high quality earnings.
Growing Profit Margin: ALONC's current net profit margins (5.5%) are higher than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: ALONC has become profitable over the past 5 years, growing earnings by 13.8% per year.
Accelerating Growth: ALONC's earnings growth over the past year (29.6%) exceeds its 5-year average (13.8% per year).
Earnings vs Industry: ALONC earnings growth over the past year (29.6%) exceeded the Biotechs industry 21.8%.
Return on Equity
High ROE: ALONC's Return on Equity (24%) is considered high.
How is Oncodesign Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: ALONC's short term assets (€23.7M) exceed its short term liabilities (€16.3M).
Long Term Liabilities: ALONC's short term assets (€23.7M) exceed its long term liabilities (€14.6M).
Debt to Equity History and Analysis
Debt Level: ALONC's debt to equity ratio (52%) is considered high.
Reducing Debt: ALONC's debt to equity ratio has increased from 1.2% to 52% over the past 5 years.
Debt Coverage: ALONC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: ALONC's interest payments on its debt are not well covered by EBIT (2.3x coverage).
What is Oncodesign Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALONC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALONC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALONC's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Philippe Genne, Ph.D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010 and Chief Corporate Business Development Offic...
Experienced Management: ALONC's management team is seasoned and experienced (11 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Oncodesign Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Oncodesign Société Anonyme
- Ticker: ALONC
- Exchange: ENXTPA
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €79.542m
- Shares outstanding: 6.83m
- Website: https://www.oncodesign.com
Number of Employees
- Oncodesign Société Anonyme
- 20 rue Jean Mazen
- BP 27627
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institu...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 21:55|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.